LSL Pharma Group Inc.
Sign in to search companies, open filing PDFs, fetch uncached SEDAR+ documents, and use the
full company research view.
News 2026-05-28
LSL Pharma Group Secures New Steri-Med Commercial Agreements Expected to Generate Over $4 Million in Recurring Annual Revenues and Appoints Alain R. Dugal as New EVP & COO
News release - English.pdf
Results 2026-05-25
LSL PHARMA GROUP REPORTS RECORD REVENUES AND FIRST QUARTER 2026 RESULTS
News release - English.pdf
Results 2026-05-22
Interim financial statements/report – English.pdf
Results 2026-05-22
Interim MD&A - English.pdf
Results 2026-05-22
Interim financial statements/report – English.pdf
Results 2026-04-30
LSL PHARMA GROUP REPORTS ITS FOURTH QUARTER AND YEAR-END 2025 RESULTS
News release - English.pdf
Results 2026-04-29
Annual report - English.pdf
Results 2026-04-29
Annual MD&A - English.pdf
Results 2026-04-29
Audited annual financial statements – English.pdf
News 2026-04-15
LSL PHARMA GROUP INC. ANNOUNCES ITS PARTICIPATION IN THE "2026 BLOOM BURTON & CO. HEALTHCARE INVESTOR CONFERENCE"
News release - English.pdf
News 2026-04-09
JUNO OTC, A WHOLLY-OWNED SUBSIDIARY OF LSL PHARMA GROUP, SIGNS BINDING TERM SHEET WITH INSTAPILL PRIVATE LIMITED TO SUPPLY PRIVATE LABEL LORATADINE 10 MG RDT IN CANADA
News release - English.pdf
News 2026-01-28
LSL PHARMA GROUP SUCCESSFULLY OBTAINED U.S. FDA CERTIFICATION FOR THE MANUFACTURING OF OPHTHALMIC OINTMENTS FOR COMMERCIALIZATION IN THE UNITED STATES
News release - English.pdf
News 2026-01-14
Report of exempt distribution (45-106F1) (amended).pdf
News 2026-01-06
Early warning report.pdf
Ownership 2026-01-06
EARLY WARNING NEWS RELEASE ISSUED PURSUANT TO THE NATIONAL INSTRUMENT 62-103
Press release - English.pdf
Transactions 2026-01-03 Financing
Groupe LSL Pharma Inc. Completes $12 Million Brokered and Non-Brokered Offering of Convertible Debentures and Acquisition of Juno OTC Inc.
Material change report - English.pdf
News 2026-01-03
Report of exempt distribution (45-106F1).pdf
Transactions 2025-12-23 M&A
LSL PHARMA GROUP ANNOUNCES CLOSING OF THE ACQUISITION OF JUNO OTC AND FINAL $2M CLOSING OF UPSIZED $12M OFFERING
News release - English.pdf
Transactions 2025-12-23 M&A
LSL PHARMA GROUP CLOSES $10M OF UPSIZED $12M BROKERED OFFERING AND ENTERS INTO DEFINITIVE AGREEMENT FOR THE ACQUISITION OF JUNO OTC
News release - English.pdf
Transactions 2025-12-17 M&A
LSL PHARMA GROUP ANNOUNCES ACQUISITION OF JUNO OTC INC. AND A BROKERED PRIVATE PLACEMENT OF CONVERTIBLE DEBENTURES OF $11M
News release - English.pdf
Results 2025-11-20
LSL PHARMA GROUP REPORTS FOURTH CONSECUTIVE RECORD QUARTERLY REVENUES AND Q3 2025 FINANCIAL RESULTS
News release - English.pdf
Results 2025-11-19 Financials
Interim MD&A - English.pdf
Results 2025-11-19 Financials
Interim financial statements/report – English.pdf
Transactions 2025-11-18 M&A
LSL PHARMA GROUP COMPLETES THE ACQUISITION OF LABORATOIRE DU-VAR INC.
News release - English.pdf
News 2025-10-28
News release - English.pdf
News 2025-10-17
NI 44-101 Notice of intent to qualify – English.pdf
Results 2025-10-17 Financials
Annual information form - English.pdf
News 2025-10-16
Material change report - English.pdf
News 2025-10-16
News release - English.pdf
News 2025-09-08
Report of exempt distribution (45-106F1).pdf
News 2025-09-02
Material change report - English.pdf
News 2025-09-02
News release - English.pdf
News 2025-08-25
News release - English.pdf
Results 2025-08-25 Financials
Interim MD&A - English.pdf
Results 2025-08-25 Financials
Interim financial statements/report – English.pdf
News 2025-08-04
News release - English.pdf
News 2025-07-31
News release - English.pdf
News 2025-07-02
News release - English.pdf
News 2025-06-27
News release - English.pdf
News 2025-06-27
News release - English.pdf